COST-EFFECTIVENESS OF UNIVERSAL OR PHENOTYPE-DRIVEN SELECTION OF DUAL ANTIPLATELET TREATMENT IN ACUTE CORONARY SYNDROME

被引：0
|
作者：
Coleman, Craig I. [1 ]
Limone, Brendan [1 ]
Lee, Soyon [1 ]
机构：
[1] Univ Connecticut, Storrs, CT USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2013年 / 61卷 / 10期
关键词：
D O I：
10.1016/S0735-1097(13)60007-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E6 / E6
页数：1
相关论文
共 50 条
  • [21] CLOPIDOGREL VERSUS ASPIRIN FOR THE TREATMENT OF ACUTE CORONARY SYNDROME AFTER A 12-MONTH DUAL ANTIPLATELET THERAPY: A COST-EFFECTIVENESS ANALYSIS FROM CHINA PAYER'S PERSPECTIVE
    Zhang, L.
    Lin, Z.
    Yin, H.
    Liu, J.
    Xuan, J.
    VALUE IN HEALTH, 2018, 21 : S60 - S60
  • [22] Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention
    Arbel, Yaron
    Bennell, Maria C.
    Goodman, Shaun G.
    Wijeysundera, Harindra C.
    CANADIAN JOURNAL OF CARDIOLOGY, 2018, 34 (01) : 31 - 37
  • [23] Cost-effectiveness analysis of genotype-guided antiplatelet therapy in patients with acute coronary syndrome and planned percutaneous coronary intervention.
    Lin, Fang-Ju
    Patel, Vardhaman
    Ojo, Olaitan
    Rao, Sapna
    Yu, Shengsheng
    Zhan, Lin
    Touchette, Daniel R.
    PHARMACOTHERAPY, 2012, 32 (10): : E300 - E300
  • [24] Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies
    Marciniak, Thomas A.
    ANNALS OF INTERNAL MEDICINE, 2014, 161 (05) : 378 - 378
  • [25] Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia
    Mejia, Aurelio
    Manuel, Juan, Sr.
    Ceballos, Mateo
    Atehortua, Sara
    Manuel Toro, Juan
    Saldarriaga, Clara
    Elena Mejia, Maria
    Ramirez, Carolina
    BIOMEDICA, 2015, 35 (04): : 531 - 540
  • [26] Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
    Wisloff, Torbjorn
    Atar, Dan
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2016, 2 (01) : 52 - 57
  • [27] COST-EFFECTIVENESS OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH RIVAROXBAN IN AUSTRALIA
    Gao, L.
    Li, S. C.
    VALUE IN HEALTH, 2014, 17 (07) : A760 - A760
  • [28] A COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS WITH ACUTE CORONARY SYNDROME IN GREECE
    Kritikou, P.
    Yfantopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A379 - A379
  • [29] COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME (ACS) PATIENTS IN SPAIN
    Thurston, S.
    Webb, C.
    Rejas, J.
    Van Hout, B.
    VALUE IN HEALTH, 2010, 13 (03) : A165 - A166
  • [30] ANALYSIS OF COST-EFFECTIVENESS AND COST-BENEFIT OF THE RIVAROXABAN ADDITION IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME IN COLOMBIA
    Romero, M.
    Marrugo, R.
    Paez, M. L.
    VALUE IN HEALTH, 2015, 18 (07) : A830 - A830
12345